comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacunas - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. el uso de esta vacuna debe estar en conformidad con las recomendaciones oficiales.
spikevax (previously covid-19 vaccine moderna)
moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacunas - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.
comirnaty original/omicron ba.4-5 15 µg/15 µg dispersion inyectable
pfizer s.a. - droguerÍa - dispersion inyectable - por dosis ml - - covid-19, rna-based vaccine
spikevax bivalent original/omicron ba.4-5 (50ug/50ug)/ml dispersion inyectable
tecnofarma s.a. - droguerÍa - dispersion inyectable - por vial 2.50 ml - - covid-19, rna-based vaccine
comirnaty original/omicron ba.4-5 (5 ug/5 ug)/0.2ml concentrado para dispersion inyectable
pfizer s.a. - droguerÍa - concentrado para dispersion inyectable - por dosis ml - - covid-19, rna-based vaccine
comirnaty original/omicron ba.4-5 (1.5 ìg/1.5 ìg)/0.2ml concentrado para dispersion inyectable
pfizer s.a. - droguerÍa - concentrado para dispersion inyectable - por dosis ml - - covid-19, rna-based vaccine
comirnaty original/omicron ba.4-5 (5 µg/5 µg)/0.3ml concentrado para dispersion inyectable
pfizer s.a. - droguerÍa - concentrado para dispersion inyectable - por dosis ml - - covid-19, rna-based vaccine
comirnaty (omicron xbb.1.5) 30 µg/0.3m dispersion inyectable
pfizer s.a. - droguerÍa - dispersion inyectable - por dosis ml - - covid-19, rna-based vaccine
comirnaty omicron xbb.1.5 10 µg/0.2 ml concentrado para dispersion inyectable
pfizer s.a. - droguerÍa - concentrado para dispersion inyectable - por dosis ml - - covid-19, rna-based vaccine
spikevax xbb.1.5 0.1 mg/ml dispersion inyectable
tecnofarma s.a. - droguerÍa - dispersion inyectable - por dosis 0.50 ml - - covid-19, rna-based vaccine